



(11)

EP 3 257 519 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 38/04 ^(2006.01) **C07K 7/00** ^(2006.01)
A61K 38/00 ^(2006.01)

(48) Corrigendum issued on:
03.06.2020 Bulletin 2020/23

(45) Date of publication and mention
of the grant of the patent:
22.04.2020 Bulletin 2020/17

(21) Application number: **17170870.4**

(22) Date of filing: **26.06.2012**

(54) **CCR2 ANTAGONIST PEPTIDES**
CCR2-ANTAGONISTENPEPTIDE
PEPTIDES ANTAGONISTES DE CCR2

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **27.06.2011 EP 11305816**

(43) Date of publication of application:
20.12.2017 Bulletin 2017/51

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
12733026.4 / 2 723 360

(73) Proprietor: **SORBONNE UNIVERSITE**
75006 Paris (FR)

(72) Inventors:
• **COMBADIÈRE, Christophe**
77700 Magny Le Hongre (FR)
• **SENNLAUB, Florian**
75011 Paris (FR)
• **AUVYNET, Constance**
75006 Paris (FR)
• **CHEMTOB, Sylvain**
Cote St Luc, Québec H4W 1G1 (CA)

• **QUINIOU, Christiane**
Montréal Québec (CA)

(74) Representative: **Cabinet Becker et Associés**
25, rue Louis le Grand
75002 Paris (FR)

(56) References cited:
WO-A2-01/31006 WO-A2-2009/106073
US-A1- 2005 037 430

• **STRUTHERS M ET AL: "CCR2 Antagonists",**
CURRENT TOPICS IN MEDICINAL CHEMISTRY,
BENTHAM SCIENCE PUBLISHERS LTD,
NETHERLANDS, vol. 10, no. 13, 1 January 2010
(2010-01-01), pages 1278-1298, XP002641076,
ISSN: 1568-0266
• **XIA MINGDE ET AL: "Recent developments in**
CCR2 antagonists.", EXPERT OPINION ON
THERAPEUTIC PATENTS MAR 2009 LNKD-
PUBMED:19441905, vol. 19, no. 3, March 2009
(2009-03), pages 295-303, XP002660853, ISSN:
1744-7674

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 3 257 519 B8

- | | |
|--|--|
| <ul style="list-style-type: none">• GONG J-H ET AL: "AN ANTAGONIST OF MONOCYTE CHEMOATTRACTANT PROTEIN 1 (MCP-1) INHIBITS ARTHRITIS IN THE MRL-LPR MOUSE MODEL", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 180, no. 1, 1 January 1997 (1997-01-01), pages 131-137, XP002919550, ISSN: 0022-1007, DOI: 10.1084/JEM.186.1.131 | <ul style="list-style-type: none">• MCQUIBBAN G ANGUS ET AL: "Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo.", BLOOD 15 AUG 2002 LNKD- PUBMED:12149192, vol. 100, no. 4, 15 August 2002 (2002-08-15), pages 1160-1167, XP002660854, ISSN: 0006-4971 |
|--|--|